Skip to main content

Table 5 Percentage utilisation of oral generic risperidone versus total risperidone (DDD basis) and percentage reduction in expenditure per defined daily dose for oral generic risperidone versus pre-patent loss prices by the end of the study period in each country

From: Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications

Country Utilisation of generic risperidone, % Price reduction, %
Belgium 52 59
Ireland 14 28
Scotland 98 84
Sweden 96 80